May 2007
Volume 48, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2007
Long Term Control of Post-LASIK Myopic Shift in High Myopia With Topical Timolol Maleate
Author Affiliations & Notes
  • J. Frucht-Pery
    Department of Ophthalmology, Hadassah-Hebrew Univ Med Ctr, Jerusalem, Israel
  • F. Orucov
    Department of Ophthalmology, Hadassah-Hebrew Univ Med Ctr, Jerusalem, Israel
  • D. Landau
    Department of Ophthalmology, Hadassah-Hebrew Univ Med Ctr, Jerusalem, Israel
  • E. Strassman
    Department of Ophthalmology, Hadassah-Hebrew Univ Med Ctr, Jerusalem, Israel
  • A. Solomon
    Department of Ophthalmology, Hadassah-Hebrew Univ Med Ctr, Jerusalem, Israel
  • Footnotes
    Commercial Relationships J. Frucht-Pery, None; F. Orucov, None; D. Landau, None; E. Strassman, None; A. Solomon, None.
  • Footnotes
    Support None.
Investigative Ophthalmology & Visual Science May 2007, Vol.48, 5334. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      J. Frucht-Pery, F. Orucov, D. Landau, E. Strassman, A. Solomon; Long Term Control of Post-LASIK Myopic Shift in High Myopia With Topical Timolol Maleate. Invest. Ophthalmol. Vis. Sci. 2007;48(13):5334.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose:: To describe the effects of topical timolol maleate on myopic regression after laser in-situ keratomielusis (LASIK).

Methods:: Timolol maleate was used twice daily in 32 eyes of 19 patients (age 29.9 ± 7.9 years) who had myopic regression and decrease of visual acuity (spherical equivalent [SEQ] of -1.00 or more). The treatment began 2-36 months after uneventful LASIK, and followed up for 10-38 months. SEQ, uncorrected visual acuity (UCVA), intraocular pressure (IOP), pre-operative pachymetry, ablation depth and number of laser pulses were recorded. The main outcome measure was the SEQ reduction during treatment with topical timolol.

Results:: The pre-operative SEQ was -9.6 ± 2.9 D (range -5.75 to -14.75) in the right eye and -9.9±2.6 (range -6.87 to -14.25) in the left eye. After 2-36 months, a residual myopia of -1.87±0.77 D (range -1 to -2.75 D) was noted in 32 eyes, and topical timolol maleate was started. After 1.78 ± 1.23 months (range 1-6 months) the SEQ was reduced to -0.94 ± 0.57 D (range 0 to -1.75 D), p<0.0001 (Wilcoxon test). The UCVA improved from 0.34 ± 0.15 to 0.63 ± 0.23 (p<0.0001, Wilcoxon test). The IOP did not change and remained stable. The reduction in SEQ correlated with the pre-operative SEQ (r=-0.48, p=0.0059), and with the post-operative SEQ before treatment was started (r=-0.69, p<0.0001). It marginally correlated with the calculated residual stromal bed (r=-0.32, p=0.072), and the pre-operative central corneal thickness (r=-0.29, p=0.09). Patients who continued the timolol use maintained a lower SEQ at the last follow up visit, compared to those who decided to discontinue the treatment (-1.00 ± 0.43 D vs. -1.59 ± 0.66 D, respectively; p=0.025, Mann-Whitney test). The time between surgery and beginning of timolol treatment did not affect the SEQ reduction.

Conclusions:: Long term treatment with topical timolol maleate reversed residual myopia and improved visual acuity after LASIK. The beneficial effect of timolol was maintained as long as the treatment continued.

Keywords: refractive surgery: complications • refractive surgery: LASIK 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×